MCLA-129

Cat. No. M49470

All AbMole products are for research use only, cannot be used for human consumption.

For this product's availability, delivery time and price, please email inquiry@abmole.com directly or click the "Inquiry Now" button below.

MCLA-129 is a 1+1 asymmetric c-Met/EGFR bispecific antibody that can be used in a variety of tumor-related studies.

Storage

Powder -20°C 3 years ; 4°C 2 years
In solvent -80°C 6 months ; -20°C 1 month

Related EGFR/HER2 Products
Panitumumab Panitumumab is a fully human IgG2 monoclonal antibody specific to the epidermal growth factor receptor (EGFR).
Nimotuzumab Nimotuzumab (Nimotuzumab) is the first humanized monoclonal antibody targeting epidermal growth factor receptor (EGFR). Nimotuzumab has cytolytic effects on target tumors through its ability to induce antibody-dependent cell-mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC). Nimotuzumab failed to recognize mouse EGFR.
Matuzumab Matuzumab (EMD 72000) is a humanized monoclonal antibody that binds tightly to EGFR.
AEE788 AEE788 (NVP-AEE788) is a novel multitargeted HER 1/2 and VEGFR 1/2 receptor family tyrosine kinases inhibitor with IC50 of 2, 6, 77, 59 nM for EGFR, ErbB2, KDR, and Flt-1.
Sapitinib (AZD8931) AZD8931 (Sapitinib) is an equipotent, reversible inhibitor of Signaling by EGFR, ERBB2 (HER2), and ERBB3 with IC50 of 4, 3, 4 nM respectively.

Catalog